I'm posting this in the ME/CFS section because the abstract mentions chronic fatigue syndrome and POTS.
http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2016.193.1_MeetingAbstracts.A5664
Recently we saw an excellent paper by Systrom's group which didn't explicitly mention CFS, though it did mention that a minority of the patients were diagnosed with POTS: Unexplained exertional dyspnea caused by low ventricular filling pressures: results from clinical invasive cardiopulmonary exercise testing
This conference abstract appears to be a follow-up study examining the use of pyridostigmine (Mestinon) in patients with exercise intolerance and preload failure. 78% response rate is claimed.
http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2016.193.1_MeetingAbstracts.A5664
First published online May 02, 2016 as doi:10.1164/ajrccm-conference.2016.193.1_MeetingAbstracts.A5664
Pyridostigmine For Exercise Intolerance Treatment In Preload Failure
Rudolf K. Oliveira , MD, PhD 1 , Julie A. Tracy , MSc 2 , Abbey L. Karin , MEd 2 , Aaron Waxman , MD, PhD 2 , David Systrom , MD, 2 ,
Publication Date: 2016
Recently we saw an excellent paper by Systrom's group which didn't explicitly mention CFS, though it did mention that a minority of the patients were diagnosed with POTS: Unexplained exertional dyspnea caused by low ventricular filling pressures: results from clinical invasive cardiopulmonary exercise testing
This conference abstract appears to be a follow-up study examining the use of pyridostigmine (Mestinon) in patients with exercise intolerance and preload failure. 78% response rate is claimed.